The norepinephrine transporter (NET) is a membrane protein responsible for termination of
the action of synaptic norepinephrine and is a site of action of many drugs used to treat major …

BACKGROUND: A deficiency of mesolimbic dopamine (DA) is a leading candidate for the
etiology of certain symptoms of depression (eg, anhedonia and loss of motivation). Here we …

Chronic sequential exposure to a variety of mild stressors has previously been found to cause
an antidepressant-reversible decrease in the consumption of palatable sweet solutions, …

BACKGROUND: Recent postmortem studies demonstrate disrupted neurochemistry of the
noradrenergic locus coeruleus (LC) in major depression (MD). Increased levels of tyrosine …

Background: Levels of tyrosine hydroxylase (TH) are regulated in the noradrenergic locus
coeruleus (LC) in response to changes in the activity of LC neurons and in response to …

Research evidence that corticotropin-releasing factor (CRF) plays a role in the pathophysiology
of major depressive disorder (MDD) has accumulated over the past 20 years. The …

The norepinephrine transporter (NET) is a site of action for tricyclic antidepressant drugs
and for drugs of abuse such as amphetamine and cocaine. In this study, the binding of [ 3 H]…

Objective: Vilazodone was recently approved by the US Food and Drug Administration (FDA)
for the treatment of major depressive disorder (MDD). The purpose of this review is to …

Repeated treatment with fluoxetine and citalopram, which are potent 5-HT reuptake inhibitors,
resulted in different regulation of 5-HT1A and 5-HT2 receptors in the rat brain. Their effects …

The binding of [ 125 I]p-iodoclonidine to alpha-2, and/or [ 125 I]iodopindolol to beta-1 and
beta-2 adrenoceptors was measured in right prefrontal cortex (Brodmann’s area 10) and right …